Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 29, 2025 • 6:00 AM ET

Date/Time Source News Release
04/23/2025 08:00 AM EDT GlobeNewswire Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors
04/15/2025 07:30 AM EDT GlobeNewswire Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases
03/27/2025 04:05 PM EDT GlobeNewswire Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
03/20/2025 07:30 AM EDT GlobeNewswire Plus Therapeutics Introduces REYOBIQ(TM), FDA-Accepted Proprietary Name for Lead Drug Candidate
03/19/2025 07:30 AM EDT GlobeNewswire Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
03/11/2025 11:00 AM EDT ACCESS Newswire D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement
03/07/2025 07:30 AM EST GlobeNewswire Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
03/06/2025 07:30 AM EST GlobeNewswire Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
03/05/2025 04:01 PM EST GlobeNewswire Plus Therapeutics Announces New Employment Inducement Grants
03/04/2025 02:06 PM EST GlobeNewswire Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
Page

Additional News

As of April 29, 2025 • 6:00 AM ET

Date/Time Source News Release
04/24/2025 08:56 AM EDT Zacks Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
04/23/2025 08:00 PM EDT Motley Fool Canada Got $5,000 to Invest? Why I'd Consider 3 Financial Stocks for My Permanent Portfolio
04/23/2025 01:30 PM EDT PRISM News PRISM Mid-Day Movers: Board Shakeups and Biotech Financings Drive Investor Focus
04/23/2025 09:32 AM EDT Zacks 5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
04/04/2025 04:40 PM EDT SeekingAlpha Plus Therapeutics files to sell 1.57B shares of common stock for holders
04/01/2025 12:00 PM EDT Zacks Plus (PSTV) Upgraded to Buy: Here's What You Should Know
03/27/2025 07:42 PM EDT SeekingAlpha Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline
03/27/2025 07:42 PM EDT SeekingAlpha Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript
03/27/2025 05:35 PM EDT Zacks Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates
03/27/2025 04:23 PM EDT SeekingAlpha Plus Therapeutics GAAP EPS of -$2.34 misses by $0.59, revenue of $5.82M beats by $0.29M
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.